Pharmacogenetic studies in depression: a proposal for methodologic guidelines (Q36904466)

17 August 2017

1 reference

title

Pharmacogenetic studies in depression: a proposal for methodologic guidelines (English)

1 reference

17 August 2017

Serretti A

1

1 reference

17 August 2017

Kato M

series ordinal

2

1 reference

17 August 2017

Kennedy JL

series ordinal

3

1 reference

17 August 2017

publication date

7 August 2007

1 reference

The Pharmacogenomics Journal

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

2

1 reference

17 August 2017

page(s)

90-100

1 reference

"A gene for...": the nature of gene action in psychiatric disorders

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Pharmacogenetics of psychotropic drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Best estimate of lifetime psychiatric diagnosis: a methodological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Stability of psychiatric diagnoses. An application to the affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Comorbidity and depression treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

The prevalence and impact of alcohol problems in major depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Comorbidity of personality disorders and unipolar major depression: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Personality disorder and the outcome of depression: meta-analysis of published studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Personality pathology in recurrent depression: nature, prevalence, and relationship to treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Personality pathology and treatment outcome in major depression: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

The molecular genetic architecture of human personality: beyond self-report questionnaires

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Predictors of response to antidepressants general principles and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Predictors of response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Factors associated with outcome in major depression: a 6-month prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Religiosity and remission of depression in medically ill older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Religious coping and depression among elderly, hospitalized medically ill men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

A comparison of antidepressant trials using active and inert placebos.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Functioning and interpersonal relationships as predictors of response in treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Quantitative rating of depressive states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Relationships among measures of treatment outcome in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Patterns of symptom improvement during antidepressant treatment of delusional depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Use of pattern analysis to identify true drug response. A replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Investigation of serotonin-related genes in antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Algorithms for optimizing the treatment of depression: making the right decision at the right time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

The medical management of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Neural network analysis in pharmacogenetics of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Pharmacogenomics in psychiatry: genomic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Association study designs for complex diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

No interaction of GABA(A) alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Use of unlinked genetic markers to detect population stratification in association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Estimated haplotype counts from case-control samples cannot be treated as observed counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Sequence analysis of the serotonin transporter and associations with antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Statistical design and analysis of pharmacogenetic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Two-week delay in onset of action of antidepressants: new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Pharmacogenetics in the treatment of depression: pharmacodynamic studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Risk for bipolar illness in patients initially hospitalized for unipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Residual symptoms after partial remission: an important outcome in depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

A neural network model for combining clinical predictors of antidepressant response in mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Classification of observational data with artificial neural networks versus discriminant analysis in pharmacoepidemiological studies--can outcome of fluoxetine treatment be predicted?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Prevalence of depression and its correlates in older adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Pseudodementia: facts and figures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

"Double depression": two-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Comorbidity of personality disorders and depression: implications for treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Is there any specific personality disorder or personality disorder cluster that worsens the short-term treatment outcome of major depression?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Chronic depression and comorbid personality disorders: response to sertraline versus imipramine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Temperament predicts clomipramine and desipramine response in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

The Tridimensional Personality Questionnaire in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Temperament dimensions explain the comorbidity of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Defensive functioning predicts improvement in major depressive episodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

The Inventory of Depressive Symptomatology (IDS): psychometric properties.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Is there a delay in the antidepressant effect? A meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Polymorphisms of the glucocorticoid receptor gene and major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Ethical problems in pharmacogenetic studies of psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Serotonin transporter gene polymorphism and antidepressant response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500477

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500477

1 reference

Dimensions Publication ID

17 August 2017

1053695803

0 references

1 reference